Vatelizumab is an investigational humanized IgG4 monoclonal antibody that targets the α2 subunit (CD49b) of very late antigen-2 (VLA-2, also known as integrin α2β1). This integrin mediates cell adhesion to extracellular matrix components (e.g., collagen) and plays roles in platelet activation, immune cell migration, and tissue repair. By blocking VLA-2 function, vatelizumab aims to inhibit pathological cell adhesion and migration, with potential applications in autoimmune diseases (such as rheumatoid arthritis and multiple sclerosis) or fibrotic disorders.